# Alger

> Alger is a VC fund in New York backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 10
- Last investment: Dec 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/fred-alger-management
- X (Twitter): http://twitter.com/algerinvest
- Website: http://www.alger.com/

Alger is a VC fund in New York focused on Biotechnology and Health Care. Fred Alger Management is an asset management arm of Fred Alger & Company Incorporated. The firm provides its services primarily to individuals. It also caters to investment companies, pooled investment vehicles, high net worth individuals, pension and profit sharing plans, charitable organizations, corporations, endowments and foundations, andstate or municipal government entities.The firm manages separate client-focused equity portfolios. It also launches and manages equity and balanced mutual funds for its clients. The firm primarily invests in the public equity and fixed income markets across the globe. It invests in growth stocks of small-cap, mid-cap, and large-cap companies. The firm employs fundamental analysis with a bottom-up stock picking approach to create its portfolios. It uses in-house research to make its investments.The firm was founded in 1964 and is based in New York City with an additional office in Jersey City, New Jersey. Fred Alger Management, Inc. operates as a subsidiary of Fred Alger & Company Incorporated.

## Contacts

5 contacts available for Alger. Shizune tracks 3 team members at Alger. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alger?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 50% |
| Health Care | 4 | 40% |
| Medical | 2 | 20% |
| Medical Device | 2 | 20% |
| Pharmaceutical | 2 | 20% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 20% |
| Funding Round | 2 | 20% |
| Series D | 1 | 10% |
| Post-IPO Debt | 1 | 10% |
| Post-IPO Equity | 1 | 10% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 50% |
| Germany | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel C. Chung | Chief Executive Officer, Chief Investment Officer, Portfolio Manager | 1 | https://shizune.co/investors/profile/daniel-c-chung |
| Michael F. DiMeglio | Executive Vice President, Chief Administrative Officer | 0 | https://shizune.co/investors/profile/michael-f-dimeglio |
| Fred Alger | Founder | 0 | https://shizune.co/investors/profile/fred-alger-2ea0 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $158M |  | Dec 10, 2025 |  |
| Forte Biosciences | Forte Biosciences is a biotechnology company that focuses on dermatology. The company's lead product, FB-401, is a topically applied live biotherapeutic developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases for the treatment of inflammatory skin disease. | $53M | Post-IPO Equity | Nov 20, 2024 |  |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $136M | Venture - Series Unknown | Feb 14, 2024 |  |
| Forte Biosciences | Forte Biosciences is a biotechnology company that focuses on dermatology. The company's lead product, FB-401, is a topically applied live biotherapeutic developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases for the treatment of inflammatory skin disease. | $25M | Post-IPO Debt | Aug 01, 2023 |  |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $101M | Venture - Series Unknown | May 12, 2022 |  |
| Prosetta Biosciences | Prosetta Corporation operates as a biopharmaceutical company in the United States. It focuses on applied science. The company was founded in 2002 and is based in San Francisco, California. | $31M | Series D | Dec 03, 2015 |  |
| Tolero Pharmaceuticals | Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatorydiseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation. The company was founded in 2011 and is based in Salt Lake City, Utah. | $8.2M | Series B | Nov 05, 2014 |  |
| Tolero Pharmaceuticals | Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatorydiseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation. The company was founded in 2011 and is based in Salt Lake City, Utah. | $14.2M | Series B | Aug 07, 2014 |  |
| ChoiceStream | ChoiceStream is a programmatic advertising partner that runs cross-device branding and direct response campaigns for brand and agency clients. ChoiceStream manages each phase of a campaign, from pre-launch planning to completion. By collecting poll-based, proprietary data specific to each client’s campaign, ChoiceStream creates custom, targetableaudiences, optimizes results in real-time, and provides unique audience insight throughout each campaign.With world-class machine-learning algorithms and a dedicated team of in-house industry experts, ChoiceStream boasts an 83% client retention rate - well above the industry average. This combination of innovative technology and personalized service ensures that clients achieve their desired metrics. For more information on ChoiceStream, | $7.5M | Series B | Jul 28, 2014 |  |
| Intarcia Therapeutics | Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating HepatitisC and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California. | $200M |  | Apr 01, 2014 |  |

10 of 10 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 2 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 2 deals together
- [Tybourne Capital Management](https://shizune.co/investors/profile/tybourne) — VC Fund, 2 deals together
- [Abiomed](https://shizune.co/investors/profile/abiomed) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Alger invest in?

Alger invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alger?

Public channels for Alger include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alger?

The team at Alger includes Daniel C. Chung (Chief Executive Officer, Chief Investment Officer, Portfolio Manager), Michael F. DiMeglio (Executive Vice President, Chief Administrative Officer) and Fred Alger (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co